Fagron NV (FAGR.BR) has a MoatMap StockRank of 95/100 based on Quality (67/100), Value (50/100), and Momentum (70/100) factor scores. The current signal is STRONG BUY. Fagron is a global leader in pharmaceutical compounding, positioning it perfectly within the CDMO pricing power theme. As drug shortages persist and personalized medicine grows, Fagron's highly regulated, essential B2B compounding facilities act as indispensable gatekeepers with immense pricing power and high switching costs.
Fagron NV is the global market leader in pharmaceutical compounding, specializing in delivering personalized medicine to hospitals, pharmacies, and patients worldwide. The company operates in a highly regulated, niche market, providing customized drug formulations that are not commercially available from mass-market pharmaceutical manufacturers. Its competitive advantage is secured by its global regulatory compliance expertise, state-of-the-art compounding facilities, and a highly consolidated market position.
| Price | $27.33 |
| Market Cap | $2.1B |
| P/E (TTM) | 19.44 |
| P/E (Forward) | 14.64 |
| Price/Book | 3.20 |
| Return on Equity | 17.2% |
| Return on Invested Capital | 13.4% |
| Debt/Equity | 84.34 |
| Gross Margin | 45.4% |
| Operating Margin | 15.1% |
| Revenue Growth | 7.6% |
| Dividend Yield | 1.7% |
| Free Cash Flow | $114M |
Fagron NV operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Belgium).